Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Genmab said its first interim analysis found statistically significant, clinically meaningful improvements in overall survival and objective response in first-line R/M patients with PD-L1+ head and neck cancer.
Genmab said the first interim analysis of its first-line trial in PD-L1-positive recurrent or metastatic head and neck cancer showed statistically significant, clinically meaningful improvement in overall survival and objective response with a petosemtamab combination.
Genmab said the combination showed statistically significant, clinically meaningful improvement in overall survival and objective response in first-line patients with recurrent or metastatic PD-L1-positive head and neck cancer.
Genmab reported statistically significant, clinically meaningful improvement in overall survival and objective response with petosemtamab combination at the first interim analysis in first-line recurrent or metastatic PD-L1-positive head and neck cancer patients.